Managed Access Programs
The FarmaMondo Group supports biopharmaceutical companies in the supply of products to patients in markets where it has not been commercially launched yet, through the implementation of Managed Access Programs, including Named Patient Supply services in more than 80 markets.
Being a preferred provider of Unlicensed Medicines to thousands of HCPs globally seeking ethical access to yet commercially unavailable therapies in their markets, the Group’s network and geographical footprint supports wider access options for the Biopharma.
The Group offers both paid access and no-charge (compassionate) access Programs through a comprehensive service package with a fair financial structure and flexible service terms.
Currently the Group operates the following Programs across various geographic regions. For more information please contact FarmaMondo offices in your region.
|Therapeutic Area||Indications||Geographical Scope|
|Cardiovascular||Acute Ischemic Stroke||Targeted regions/countries|
|Acute Myocardial infarction||Targeted regions/countries|
|Arterial Hypertension||Targeted regions/countries|
|Idiopathic or heritable pulmonary arterial hypertension (PAH)||Targeted regions/countries|
|Hematology Orphan||Paroxysmal Nocturnal Hemoglobinuria (PNH)||Targeted regions/countries|
|Infectious Diseases & Virology||Viral CMV retinitis; Mucocutaneous Acyclovir Resistant HSV Infections||Targeted regions/countries|
|Metabolic Disease Orphan||Wilson's disease (orphan)||Targeted regions/countries|
|Congenital Generalized Lipodystrophy||Targeted regions/countries|
|Homozygous Familial Hypercholesterolemia||Targeted regions/countries|
|Alagille syndrome (ALGS)||Targeted regions/countries|
|Progressive familial intrahepatic cholestasis (PFIC)||Targeted regions/countries|
|Nephrology Orphan||Atypical Hemolytic Uremic Syndrome (aHUS)||Global|
|Duchenne Muscular Dystrophy||Targeted regions/countries|
|Oncology||Epithelial ovarian cancer / fallopian tube cancer||Targeted regions/countries|
|Chemotherapy induced neutropenia||Targeted regions/countries|
|Onco-haematology||Acute Promyelocytic Leukemia||Targeted regions/countries|
|Multiple myeloma, melanoma, amyloidosis, sarcoma||Targeted regions/countries|
|Acute Lymphoblastic Leukemia (ALL)||Global|
|Ophthalmology Orphan||Neurotrophic Keratitis||Targeted regions/countries|
|Pediatric Oncology||Neuroblastoma||Targeted regions/countries|
|Transplantation||Conditioning agent for bone marrow transplantation||Targeted regions/countries|